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Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell,
Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP)
and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and
increases accessibility of tumor cells to anticancer drugs.Pancreatic ductal adenocarcinoma (PDA)
is among the most lethal human malig-
nancies due to its insidious onset and
resistance to therapy. Most anticancer
drugs, including standard-of-care gemci-
tabine and novel molecular targeted
therapies that have displayed impressive
activity against PDA cells in culture and
in some preclinical animal models, yield
little success in the clinic (Li et al., 2010).
Sensitivity of neoplastic cells in such
models is a poor predictor of clinical
effectiveness.
In addition to epigenetic and genetic
alterations in cancer cells that influence
drug sensitivity, the tumor microenviron-
ment mediates responses of solid tumors
to chemotherapy (Tre´dan et al., 2007).
The vasculature of solid tumors is disor-
ganized compared to that in normal
tissues, with variable blood flow and large
distances between functional capillaries.
This leads to gradients from tumor
blood vessels of nutrients, with regions
of hypoxia and extracellular acidity and
gradients in tumor cell proliferation (Fig-
ure 1). Anticancer drugs are delivered
through blood vessels, and gradients in
their concentration are established within
tumors; cells distal from blood vessels are
likely to be resistant to systemic therapy
because of low drug concentration and
because most drugs, including many
targeted agents, are more active against
rapidly-proliferating cells. A dense extra-
cellular matrix (ECM) and stromal com-
ponents of tumors increase interstitial
fluid pressure (IFP), which limits ability of
larger molecules, including therapeuticantibodies, to penetrate tumor tissue
by convection; if IFP exceeds capillary
pressure, vascular collapse will occur,
limiting delivery of all drugs (and nutrients)
to the tumor. The above factors are partic-
ularly relevant to PDA, which usually has
a dense desmoplastic stroma with fibrotic
connective tissue that surrounds the
tumor and may account for >80% of
tumor volume (Erkan et al., 2010). This
leads to a microenvironment with low
blood perfusion and hypoxia, serving as
a ‘‘wall-like’’ barrier to diminish the deliv-
ery of anticancer drugs and stimulating
aggressive tumor cell behavior (Neesse
et al., 2011). The amount of reactive
stroma is an independent predictor for
poor prognosis of patients with PDA
(Erkan et al., 2008). Hence, targeting
non-neoplastic components within the
microenvironment provides an oppor-
tunity for developing more effective
therapies.
In this issue ofCancer Cell, Provenzano
et al. (2012) characterize histologically
various stromal components in prein-
vasive, invasive, and metastatic pancre-
atic tissues in mice and humans. They
and others have shown that autoch-
thonous PDA in KrasLSL-G12D/+;Cre and
KrasLSL-G12D/+;Trp53LSL-R172H/+;Cre con-
ditional knockout mice provide excellent
models for human PDA (see also Olive
et al., 2009). Provenzano and colleagues
demonstrate that the content of collagen
and glycosaminoglycans increases pro-
gressively with histopathological grade
from early precusor lesions to invasive
and metastatic PDA tumors. The expres-Cancer Cell 2sion and abundance of hyaluroic acid
(HA), a large linear glycosaminoglycan
associated with inflammation, wound
repair, and tissue remodelling (Toole,
2004), are elevated during carcinogen-
esis. These findings, along with similar
observations in other solid tumors (Toole,
2004), suggest that accumulation of HA
contributes to neoplastic transformation,
tumor progression, and drug resistance
in PDA. Using three-dimensional ma-
trices, the investigators demonstrate that
the presence of HA can directly elevate
IFP. The authors measure IFP in murine
PDA and find a range of 75–130 mm Hg,
much larger than values in the normal
pancreas or than capillary blood pressure
(range: 8–13 mm Hg). These extremely
high levels of IFP induce vascular collapse
and limit availability of drugs to the tumor.
In this issue of Cancer Cell, Provenzano
et al. (2012) then evaluate intravenous
administration of PEGPH20, a HA-target-
ing enzymatic agent, in mice bearing
autochtonous PDA. PEGPH20 depletes
HA in the tumor matrix, resulting in a
marked reduction in IFP, increased diam-
eter of CD31+ blood vessels, increased
patent vessels, and improved penetration
of doxorubicin in PDA. They compare
treatment with gemcitabine with or with-
out PEGPH20 in cohorts of mice bearing
autochtonous PDA. Gemcitabine alone
has negligible effects, but the combina-
tion leads to reduced tumor size and
increased apoptosis of tumor cells with
all tumors responding after three cycles.
Combined treatment decreases meta-
static tumor burden and increases overall1, March 20, 2012 ª2012 Elsevier Inc. 327
Figure 1. Strategies to Overcome the Effects of Limited Drug Distribution in Solid Tumors
Drug distribution in solid tumors is determined by various factors including molecular size and charge,
consumption of drugs by cells proximal to blood vessels, and the volume and organization of the extra-
cellular matrix (ECM). As shown by Provenzano et al. (2012), modification of the ECM can lead to
a decrease of high interstitial fluid pressure (IFP) and an increase of tumor blood flow, allowing greater
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Previewssurvival of animals when compared to
either agent used alone. These thera-
peutic effects are accompanied by exten-
sive remodeling of tumor stroma and
maintainance of a functional vasculature.
In light of these promising results and
encouraging data from phase I clinical
trials, a phase II trial has been intitiated to
investigate the effects of gemcitabine +
PEGPH20 in the treatment of patients
with advanced, previously-untreated PDA
(http://www.clinicaltrials.gov).
Other investigators have used strate-
gies to improve vascular perfusion and
drug delivery in PDA. Olive et al. (2009) re-
ported that depletion of tumor-associated
stromal fibroblasts by disrupting Hedge-
hog signaling increased intratumoral
vascular density transiently via neoangio-
genesis and resulted in improved delivery
and greater antitumor activity of gemcita-
bine using the same mouse model of
PDA. Two drugs that inhibit the Hedgehog
pathway (GDC-0449 and LDE225) are
being evaluated with chemotherapy in
phase II clinical trials for PDA (http://
www.clinicaltrials.gov).
Will these strategies translate into
improved outcome for people with ad-
vanced PDA? Targeting the tumor micro-
environment is an innovative approach
worthy of study in cinical trials, especially
for a disease where other strategies have
yielded only minor improvements in
outcome. However, all mice in the preclin-
ical trials conducted by Provenzano et al.
(2012) eventually die of their tumors.
Even if enzymatic treatment can lead to
vascular remodeling and increased perfu-
sion in human PDA, there remain gradi-
ents in drug concentration in relation to
tumor blood vesseels and resistance
of poorly-nourished slowly-proliferating
cells to anticancer drugs, a problem com-
mon to solid tumors (Tre´dan et al., 2007).
As shown by Huxham et al. (2004), tumor
repopulation is intiated from cells distant
from blood vessels when transplantedaccess of cytotoxic agents to tumor cells. Other
strategies to improve drug distribution (indicated
schematically by red arrows and dashed lines)
include augmentation of tumor blood flow and
inhibition of drug sequestration in cells close to
blood vessels. Combined treatment with con-
ventional therapeutics and drugs that both diffuse
to and target cells distant from blood vessels
(e.g., hypoxia-activated prodrugs and agents that
target autophagy) may also improve therapeutic
effectiveness.
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Previewshuman colorectal xenografts are treated
with gemcitabine.
The major contributions of Olive et al.
(2009) and Provenzano et al. (2012) are
in demonstrating the importance of the
microenvironment of PDA, and of solid
tumors in general, in determining resis-
tance to drug therapy. The majority of
research on drug resistance has concen-
trated on molecular properties of indi-
vidual cancer cells. Although intrinsic
sensitivity is important, it is only part of
the story—stated simply, if a drug does
not get to some of the tumor cells, they
will not be killed no matter how sensitive
they might be to the drug in cell culture.
More research should focus on strate-
gies that recognize the importance of
the tumor microenvironment and drug
delivery in limiting therapeutic efficacy.
There are several approaches to this
problem, some of which are outlined in
Figure 1. They include strategies to target
the ECMwith enzymes such as PEGPH20
or inhibition of Hedgehog signaling, strat-
egies to decrease drug sequestration in
cells proximal to blood vessels therebyallowing better distribution of drugs to
distal cells, and combination treatment
using ‘‘conventional’’ therapeutics to-
gether with drugs that both diffuse to
and target specifically cells distant from
blood vessels. Promising drugs for the
latter include hypoxia-activated prodrugs
and agents that attack the process of
autophagy, a survival mechanism for
stressed tumor cells (Tre´dan et al., 2007;
Yang et al., 2011).
In summary, the efficiency of systemic
chemotherapy for PDA in particular and
for solid tumors in general is hindered by
poor delivery of drugs to some tumor
regions and by effects of the tumor micro-
environment on drug activity. As Proven-
zano and coworkers show convincingly,
agents that improve drug delivery by
modifying factors relating to the tumor
microenvironment represent an important
future direction for cancer therapy.REFERENCES
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Recent genomic analyses of pediatric glioblastoma, a poorly understood tumor with dismal outcome, have
identified mutations in histone H3 variants that affect critical amino acids in the tail. The findings extend
discoveries of chromatin regulator inactivation and gain-of-function mutations by documenting alteration
of a modifiable histone residue in human cancer.Brain tumors are the most common solid
neoplasms of childhood and the primary
cause of cancer-related deaths in chil-
dren. Although their pathological classifi-
cation is complex, most high-grade brain
tumors in children are categorized as
either embryonal (such as medulloblas-
toma) or glial (such as the diffusely infiltra-tive glioblastoma [GBM]). An anatomical
variant of high-grade glioma, diffuse in-
trinsic pontine glioma (DIPG), is a parti-
cularly vexing clinical challenge given its
location in the neurologically critical brain
stem. Over the past few decades, major
progress has been made in the under-
standing and treatment of children withmedulloblastomas, but little real progress
has been made in the treatment of chil-
dren with malignant diffuse gliomas.
Consistent prognostic estimates have
been difficult to establish, since the
clinical behavior of childhood diffuse
gliomas is not as stereotypical as that of
their more common adult counterpart.1, March 20, 2012 ª2012 Elsevier Inc. 329
